Ex Vivo News and Research

RSS

Vaccine developed at Rockefeller University boosts natural killer T cells in patients with cancer

A new vaccine designed at The Rockefeller University boosted a type of fast-responding immune system cell called the natural killer T (NKT) cell in patients with advanced cancer. The study surprised researchers by revealing the ability of these NKT cells to spur other, slower-responding immune cells to go to work.

4 May 2005

Halozyme Therapeutics receives FDA clearance for Cumulase

Halozyme Therapeutics has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase is the first and only recombinant human hyaluronidase approved in the United States for cumulus removal in the IVF process.

20 Apr 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

One-third of U.S. adults use some form of alternative medicine

More than one-third of U.S. adults use some form of alternative medicine such as herbal supplements and other therapies, showed in a nationwide survey by NIH's National Center for Complementary and Alternative Medicine published in May 2004.

2 Aug 2004

3-D micro-imaging technology licensed to Carl Zeiss Jena by Cornell

Biomedical microscopic imaging deep inside living tissue with unprecedented clarity could become routine and widely available with the signing of technology-transfer and collaborative-research agreements today (May 28, 2004) by Carl Zeiss Jena GmbH, a leading maker of microscopy instrumentation, and by CCTEC, the technology, enterprise and commercialization arm of Cornell University.

30 May 2004

Functional genomics and proteomics may accelerate the discovery of new drugs and therapeutic molecules

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.

29 Apr 2004

Functional genomics provide improved drug discovery

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.

20 Apr 2004

Ex Vivo News and Research

Vaccine developed at Rockefeller University boosts natural killer T cells in patients with cancer

Halozyme Therapeutics receives FDA clearance for Cumulase

Potential new therapies for cancer and bleeding disorders

One-third of U.S. adults use some form of alternative medicine

3-D micro-imaging technology licensed to Carl Zeiss Jena by Cornell

Functional genomics and proteomics may accelerate the discovery of new drugs and therapeutic molecules

Functional genomics provide improved drug discovery

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News